DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,053 filers reported holding DANAHER CORPORATION in Q2 2023. The put-call ratio across all filers is 0.79 and the average weighting 0.5%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $80,880,600 | -60.0% | 326,000 | -61.3% | 1.16% | -70.0% |
| Q2 2023 | $202,008,000 | -11.5% | 841,700 | -7.1% | 3.89% | -9.5% |
| Q1 2023 | $228,348,240 | +150.5% | 906,000 | +227.0% | 4.30% | +679.9% |
| Q4 2021 | $91,147,000 | -83.7% | 277,035 | -84.9% | 0.55% | -82.4% |
| Q3 2021 | $558,471,000 | -11.1% | 1,834,421 | -21.7% | 3.12% | -24.0% |
| Q2 2021 | $628,344,000 | +5.1% | 2,341,421 | -11.8% | 4.11% | -7.1% |
| Q1 2021 | $597,634,000 | +4.2% | 2,655,206 | +2.8% | 4.42% | +63.3% |
| Q4 2020 | $573,642,000 | +94.2% | 2,582,346 | +88.2% | 2.71% | +56.6% |
| Q3 2020 | $295,386,000 | -47.9% | 1,371,781 | -57.2% | 1.73% | -59.1% |
| Q2 2020 | $566,485,000 | +5.4% | 3,203,556 | -17.5% | 4.22% | -23.9% |
| Q1 2020 | $537,220,000 | +239.1% | 3,881,366 | +223.4% | 5.56% | +94.2% |
| Q1 2019 | $158,424,000 | +136.4% | 1,200,000 | +84.6% | 2.86% | +122.2% |
| Q4 2018 | $67,028,000 | – | 650,000 | – | 1.29% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |